https://orcid.org/0000-0002-5669-2515
References
- Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
- Stillwell W. Membrane Transport. An Introduction to Biological Membranes. 2016: 423–451
- Kebede MA, Alquier T, Latour MG, et al. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11(Suppl 4):10–20.
- van Dalen A, de Kruijff B. The role of lipids in membrane insertion and translocation of bacterial proteins. Biochim Biophys Acta. 2004;1694(1–3):97–109.
- Yin H, Chu A, Li W, et al. Lipid G protein-coupled receptor ligand identification using beta-arrestin pathhunter assay. J Biol Chem. 2009;284(18):12328–12338.
- Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018;28(3):109–118.
- Letsinger RL, Zhang G, Sun DK, et al. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proceedings of the National Academy of Sciences. 1989;89(17):6553–6556.
- Winkerler J. Oligonucleotide conjugates for therapeutic applications. Ther Deliv. 2013;4(7):791–809.
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide‑1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
- Biscans A, Caiazzi J, McHugh N, et al. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol Ther. 2020;29(4):1382–1394.
- Osborn MF, Coles AH, Biscans A, et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids Res. 2019;47(3):1070–1081.
- Østergaard ME, Jackson M, Low A, et al. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res. 2019;47(12):6045–6058.
- Sukow A, Inventor; DTX PHARMA, INC., assignee. Lipid-modified nucleic acid compounds and methods. World Intellectual Patent Organization WO2019/232255 A1. 2019 Dec 5
- Dikmen G, Gellert C, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005;65(17):7866–7873.
- Herbert B-S, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3’-->P5’ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24(33):5262–5268.
- Echevarría L, Aupy P, Relizani K, et al. Evaluating the impact of variable phosphorothioate content in tricyclo-DNA antisense oligonucleotides in a duchenne muscular dystrophy mouse model. Nucleic Acid Ther. 2019;29(3):148–160.
- Relizani K, Echevarría L, Zarrouki F, et al. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides. Nucleic Acids Res. 2022;50(1):17–34.
- Moumné L, Marie AC, Crouvezier M. Oligonucleotide therapeutics: from discovery and development to patentability. Pharmaceutics. 2022;14(2):260–284.
- Chapell AE, Gaus HJ, Berdeja A, et al. Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice. Nucleic Acid Res. 2020;48(8):4382–4395.
- Wang S, Allen N, Prakash TP, et al. Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells. Nucleic Acid Ther. 2019;29(5):245–255.
- Brown KM, Nair JK, Janas MM, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40(10):1500–1508.